Patent Application: Janus Kinase Inhibitors by Chiesi Farmaceutici

The USPTO has published a patent application (US20260085077A1) filed by Chiesi Farmaceutici S.P.A. The application describes compounds of general formula (I) that inhibit Janus Kinase (JAK) family kinases. These compounds are intended for therapeutic use in treating inflammatory diseases.

Patent Application for Crystal Form of Aromatic Heterocyclic Compound

The USPTO has published a patent application (US20260085076A1) detailing a new crystal form (I and III) of an aromatic heterocyclic compound. The application also describes a production method and its use in treating diseases related to abnormal JAK-STAT signaling pathways.

Protein Degraders Patent Application

The USPTO has published a new patent application, US20260085075A1, related to protein degraders and their uses. The application was filed on August 19, 2025, by inventors Nello Mainolfi, Nan Ji, Yi Zhang, and Matthew M. Weiss.

Patent Application: Cancer Treatment Compositions and Methods

The USPTO has published a patent application (US20260085074A1) detailing compositions and methods for treating cancer by modulating K-Ras, a frequently mutated oncogene. The application was filed on June 17, 2025, by inventors Jonathan Ostrem, Ulf Peters, and Kevan M. Shokat.

Patent Application for Pyrazolylcarboxamide Compounds for Therapy

The USPTO has published a patent application (US20260085073A1) for pyrazolylcarboxamide compounds and their use in therapy. The application details compounds that inhibit MALT1 and their potential treatment for proliferative, inflammatory, or autoimmune disorders.

Method for Preparing Intermediate of Adrenergic Receptor Agonist

The USPTO has published a patent application detailing a new method for preparing an intermediate of an adrenergic receptor agonist. The method claims to offer improved yield, reduced cost, and milder reaction conditions, making it more favorable for commercial production. The application was filed on December 4, 2025.

Patent Application for Novel Crystalline Form of Amine Compound

The USPTO has published a patent application (US20260085071A1) for novel crystalline forms of an amine compound, 1-(8-bromopyrido[2,3-e][1,2,4]triazolo[4,3-a]pyrazin-4-yl)-N-methylazetidin-3-amine. The application also discloses pharmaceutical compositions and the use of these forms for treating diseases such as atopic dermatitis and urticaria.

Patent Application for Cancer Treatment Compounds

The USPTO has published a new patent application (US20260085070A1) for heterocyclic CBL-B inhibitors intended for the treatment of cancer. The application was filed on April 7, 2025, by inventors Yingzhi BI, Kenneth G. CARSON, and Geraldine Cirillo HARRIMAN.

USPTO Patent Application for Cancer Prodrugs

The USPTO has published a patent application (US20260085069A1) for novel prodrug compounds designed to treat cancer and other diseases by inhibiting Casein Kinase 2 alpha (CK2α). The application details specific chemical structures and their potential pharmaceutical uses.

Pritelivir Crystalline Form Patent Application

The USPTO has published a patent application (US20260085068A1) filed by Assembly Biosciences, Inc. on August 28, 2023. The application describes a novel crystalline form of the antiviral drug pritelivir, intended for the treatment of herpes virus.